Back to Search
Start Over
Is there an increased risk of severe COVID-19 among patients with systemic lupus erythematosus treated with anifrolumab?
- Source :
- Lupus; Mar2023, Vol. 32 Issue 3, p453-455, 3p, 1 Chart
- Publication Year :
- 2023
-
Abstract
- After three anifrolumab infusions, she developed cough, sore throat, headache, muscle pain, and a COVID-19 was confirmed by PCR and serological test (2 months later). After three infusions of anifrolumab, she developed cough, sore throat, and headache and a COVID-19 was diagnosed using Polymerase Chain reaction (PCR). [Extracted from the article]
Details
- Language :
- English
- ISSN :
- 09612033
- Volume :
- 32
- Issue :
- 3
- Database :
- Complementary Index
- Journal :
- Lupus
- Publication Type :
- Academic Journal
- Accession number :
- 162418049
- Full Text :
- https://doi.org/10.1177/09612033231153536